CURASIGHT A/SCURASIGHT A/SCURASIGHT A/S

CURASIGHT A/S

No trades
See on Supercharts

CURAS fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Curasight A/S is a clinical development company. It engages in the business of exploiting a novel theragnostic platform with positron emissions tomography imaging and radionuclide therapy targeting the urokinase-type plasminogen activator receptor. The company was founded by Morten Persson, Andreas Kjær, Carsten Haagen Nielsen, and Jacob Madsen in 2013 and is headquartered in Copenhagen, Denmark.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
CURAS has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company